12:00 AM
 | 
Jun 24, 2013
 |  BC Week In Review  |  Company News  |  Deals

Transition Therapeutics, Eli Lilly deal

Transition said Eli Lilly exercised its option to assume all development and commercialization rights to Type II diabetes compound TT-401, triggering a $7 million milestone payment to Transition. Eli Lilly said the partners amended the deal to secure a greater vested interest for Transition in a...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >